Evaluation of the preventive effect of intravenous flurbiprofen axetil against mesenteric traction syndrome by continuous measurement of systemic vascular resistance index using a FloTrac sensor.

Evaluation of the preventive effect of intravenous flurbiprofen axetil against mesenteric traction syndrome by continuous measurement of systemic vascular resistance index using a FloTrac sensor. - Evaluation of MTS using a FloTrac sensor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007782

Enrollment

Registered

2012-04-23

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients scheduled for elective open abdominal surgery

Interventions

In flurbiprofen administration group, 50mg of flurbiprofen is injected intravenously after the induction of anesthesia. In control group, patients receive no injections at those times.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients (American Society of Anaesthesiologists physical status [ASA-PS] 1-2 ) scheduled for elective open abdominal surgery

Exclusion criteria

Exclusion criteria: Patient who is taking any steroidal or non-steroidal anti-inflammatory drug (NSAID) that might influence COX activities.

Design outcomes

Primary

Measure	Time frame
If mesenteric traction syndrome (MTS) occurs, a decline of the systemic vascular resistance (SVR) will be observed. If MTS can be prevented, SVR will be maintained.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026